InvestorsHub Logo
Followers 32
Posts 2811
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Sunday, 10/09/2022 8:23:15 PM

Sunday, October 09, 2022 8:23:15 PM

Post# of 29
The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LYEL News